

Erica L Mayer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/205911/publications.pdf>

Version: 2024-02-01

46
papers

4,413
citations

257450

24
h-index

233421

45
g-index

47
all docs

47
docs citations

47
times ranked

6673
citing authors

#	ARTICLE	IF	CITATIONS
1	Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology. <i>Cancer</i> , 2022, 128, 275-283.	4.1	5
2	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 449-458.	1.6	25
3	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	1.6	88
4	Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic. <i>Lancet Oncology</i> , The, 2022, 23, 195-197.	10.7	4
5	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	7.0	22
6	Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?. <i>Lancet Oncology</i> , The, 2022, 23, 325-328.	10.7	1
7	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	1.6	139
8	Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 597-606.	2.5	5
9	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	10.7	169
10	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4883-4897.	7.0	11
11	Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel. <i>Radiology</i> , 2021, 300, E323-E327.	7.3	117
12	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. <i>Journal of Clinical Oncology</i> , 2021, 39, 2539-2551.	1.6	78
13	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 103.	5.2	17
14	Reply to T. Shimoi et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	1.6	3
15	Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2021, 17, 541-545.	2.9	3
16	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	7.0	91
17	Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 190-192.	4.0	0
18	Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during Pregnancy. <i>American Journal of Perinatology</i> , 2020, , .	1.4	2

#	ARTICLE	IF	CITATIONS
19	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	7.0	109
20	Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer. <i>Breast Journal</i> , 2019, 25, 1104-1110.	1.0	10
21	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. <i>Clinical Breast Cancer</i> , 2019, 19, 399-404.	2.4	27
22	Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580.	10.7	191
23	Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 664-674.	2.4	39
24	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	91
25	Treatment of Breast Cancer During Pregnancy. <i>Current Breast Cancer Reports</i> , 2017, 9, 195-201.	1.0	0
26	Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors. <i>Cancer</i> , 2017, 123, 1249-1258.	4.1	87
27	Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptorâ€“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2866-2870.	1.6	12
28	Chemotherapy for Triple-Negative Breast Cancer: Is More Better?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3369-3371.	1.6	24
29	Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. <i>Oncologist</i> , 2016, 21, 666-670.	3.7	17
30	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	1.6	141
31	Targeting Breast Cancer with CDK Inhibitors. <i>Current Oncology Reports</i> , 2015, 17, 443.	4.0	67
32	Cardiovascular Health of Patients With Cancer and Cancer Survivors. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2739-2746.	2.8	198
33	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 2361-2369.	1.6	197
34	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1902-1909.	1.6	351
35	Postmenopausal breast cancer: a best endocrine strategy?. <i>Lancet</i> , The, 2015, 386, 1317-1319.	13.7	8
36	Adjuvant endocrine therapy for postmenopausal women: Type and duration. <i>Breast</i> , 2015, 24, S126-S128.	2.2	5

#	ARTICLE	IF	CITATIONS
37	Early and Late Long-Term Effects of Adjuvant Chemotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 9-14.	3.8	14
38	Breast Cancer Survivors' Perceptions of Survivorship Care Options. Journal of Clinical Oncology, 2012, 30, 158-163.	1.6	64
39	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2012, 30, 2615-2623.	1.6	413
40	Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Research and Treatment, 2012, 136, 169-178.	2.5	40
41	A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research, 2011, 17, 6897-6904.	7.0	90
42	Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans. Hypertension, 2011, 58, 85-92.	2.7	47
43	Anti-Angiogenic Strategies in Breast Cancer: An Update. Current Breast Cancer Reports, 2010, 2, 174-181.	1.0	1
44	Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer. Journal of Clinical Oncology, 2008, 26, 556-562.	1.6	432
45	Chemotherapy for Metastatic Breast Cancer. Hematology/Oncology Clinics of North America, 2007, 21, 257-272.	2.2	72
46	Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature, 1995, 373, 432-434.	27.8	880